Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 5;39(8):1081–1090.e2. doi: 10.1016/j.ccell.2021.06.002

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Inc.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Association of anti-SARS-CoV-2 spike IgG with type of therapy and prior COVID-19 history

(A) Anti-spike protein IgG antibody titers (AU/mL) after full vaccination did not significantly differ in patients receiving immune checkpoint inhibitor (ICI) therapy when compared with those who did not.

(B) Patients receiving hormonal therapy had a significantly higher titer after vaccination.

(C) Patients receiving CDK4/6 inhibitor therapy had a significantly lower titer after vaccination.

(D) Patients with prior COVID-19 infection had significantly higher IgG titers.

Box plots are shown with differences assessed by Kruskal-Wallis test.